Evidence Snapshot

Human immunodeficiency virus type 1 integrase

CHEMBL3471 SINGLE PROTEIN Human immunodeficiency virus 1

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:20Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 7:20 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL3471

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Human immunodeficiency virus type 1 integrase as ChEMBL target CHEMBL3471, mapped to UniProt Q7ZJM1. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Human immunodeficiency virus type 1 integrase

SINGLE PROTEIN · Human immunodeficiency virus 1

As of 2026-09-13

ChEMBL target ID

CHEMBL3471

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

Q7ZJM1

Gag-Pol polyprotein

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Human immunodeficiency virus type 1 integrase matters

As of 2026-09-13

Human immunodeficiency virus type 1 integrase is reviewed as Gag-Pol polyprotein (UniProt Q7ZJM1); Human immunodeficiency virus type 1 integrase shows approved-linked disease relevance led by HIV infection. 5 more disease programs remain visible in the same review block.; 8 linked drugs keep this evidence frame grounded.; the current evidence base includes 13 approved drugs, 5082 compounds, and 808 assays, with lead potency reaching pChEMBL 9.7.

Protein context

Gag-Pol polyprotein

Gag-Pol polyprotein Sequence length is 288 aa.

Review this target as Human immunodeficiency virus type 1 integrase, mapped to UniProt Q7ZJM1. ChEMBL maps the protein component as Gag-Pol polyprotein. Sequence length is 288 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt Q7ZJM1 Protein

Disease context

HIV infection

Human immunodeficiency virus type 1 integrase shows approved-linked disease relevance led by HIV infection. 5 more disease programs remain visible in the same review block. 8 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BICTEGRAVIR, BICTEGRAVIR SODIUM, CABOTEGRAVIR.

Start review with HIV infection because it currently carries approved-linked support. Linked drugs include BICTEGRAVIR, BICTEGRAVIR SODIUM, CABOTEGRAVIR, DOLUTEGRAVIR SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 8 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 13 approved drugs, 5082 compounds, and 808 assays for this target. The dominant activity type is IC50. CHEMBL204656 is the current potency anchor at pChEMBL 9.7.

Use CHEMBL204656 as the tractability anchor when discussing potency (pChEMBL 9.7).

Activity source · ChEMBL 36 via Core Engine

13 approved pChEMBL 9.7

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Human immunodeficiency virus type 1 integrase matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q7ZJM1, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why HIV infection is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

5082

Total Compounds

808

Total Assays

Approved Drugs

IC50: 7994.0, KI: 25.0, EC50: 91.0, KD: 58.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL204656	9.7	EC50	Approved
No preferred name CHEMBL1229211	9.3	IC50	Approved
No preferred name CHEMBL414850	9.3	IC50	—
No preferred name CHEMBL3805182	9.2	IC50	—
No preferred name CHEMBL3806067	9.2	IC50	—